Citation only
via Europe PMC
Deanna Protocol Ameliorates the Deficits in Human iPSC-Cortical Neurons Carrying Familial Alzheimer's Mutation.
Keler Soares L, Srivastava G, Dwelle C, Waggoner B, Tedone V, Hickman JJ, Guo X.
CNS neuroscience & therapeutics · 2026
Abstract
<h4>Aims</h4>Deanna Protocol (DP) is an anaplerotic, mechanism-based therapy designed to address impaired cellular energy flux. The present study aims to investigate the effects of DP in treating Alzheimer's disease (AD) by using cortical neurons derived from AD patient iPSCs carrying a PSEN1 mutation, while cortical neurons differentiated from iPSCs of a healthy subject serve as control.<h4>Methods</h4>PSEN1 cortical neurons were treated with DP acutely (24 h) and chronically (1-3 weeks). The effect of DP was assessed by utilizing TMRE assay for mitochondrial function, immunofluorescent staining for AD neuron morphological pathology, whole cell patch clamp for neuron electrophysiological property, and microelectrode array (MEA) analysis of long-term potentiation (LTP) for neurocircuit function.<h4>Results</h4>PSEN1 cortical neurons demonstrated impaired mitochondrial function, elevated pathological biomarkers, reduced neurite complexity, altered electrophysiology, and decreased LTP. DP treatment significantly ameliorated all these phenotypes.<h4>Conclusion</h4>This study, while confirming iPSC-PSEN1 cortical neurons as a valid AD model, demonstrated the efficacy of DP on ameliorating structural and functional pathologies in AD neurons. It highlights that targeting energy production could be an effective approach in treating neurodegeneration in AD and suggests its potential efficacy in other neurodegenerative diseases.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1002/cns.71205
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
L, K.S., G, S., C, D., B, W., V, T., JJ, H., & X., G. (2026). Deanna Protocol Ameliorates the Deficits in Human iPSC-Cortical Neurons Carrying Familial Alzheimer's Mutation. <em>CNS neuroscience & therapeutics</em>. https://doi.org/10.1002/cns.71205
Vancouver
L KS, G S, C D, B W, V T, JJ H, et al. Deanna Protocol Ameliorates the Deficits in Human iPSC-Cortical Neurons Carrying Familial Alzheimer's Mutation. CNS neuroscience & therapeutics. 2026. doi:10.1002/cns.71205.
BibTeX
@article{keler2026Deanna,
title = {Deanna Protocol Ameliorates the Deficits in Human iPSC-Cortical Neurons Carrying Familial Alzheimer's Mutation.},
author = {Keler Soares L and Srivastava G and Dwelle C and Waggoner B and Tedone V and Hickman JJ and Guo X.},
journal = {CNS neuroscience & therapeutics},
year = {2026},
doi = {10.1002/cns.71205},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Proceedings of the National Academy of Sciences 2016
Open access · OA
Loss of O -GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration
National Taiwan University Hospital 2018
Open access · US-GOV
Multimodal Biomarkers for Diagnosis and Prognosis in Cerebral Amyloid Angiopathy
Frontiers in Pharmacology 2019
Open access · CC-BY
Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update
HAL 2018
Preprint · OA
Le rôle de l’AMPK dans le vieillissement et la perte de plasticité neuronale liée au vieillissement chez C. elegans
biorxiv 2025
Preprint · CC-BY
Early cell cycle genes in cortical organoid progenitors predict interindividual variability in infant brain growth trajectories
African Journal of Biomedical Research 2024
Open access · OA